Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block.
BACKGROUND
The factors that influence the onset time of submaximal (<100%) neuromuscular block are not fully known. The authors hypothesized that differences in the rate of decrease in the plasma concentration result in differences in the rate of equilibration between plasma and biophase and thus in different onset times. If this hypothesis is valid, inhibition of the enzymic degradation of muscle relaxants should increase the onset time of neuromuscular block.


METHODS
Twenty pigs received either suxamethonium or mivacurium. Dose finding (70% block) was done for each pig. The enzymic degradation of the muscle relaxant was randomly inhibited by selective inhibition of plasma cholinesterase activity by tetraisopropyl pyrophosphoramide (10 pigs) or was not inhibited (10 pigs). Plasma cholinesterase activities and the mechanomyographic muscle response after peroneal nerve stimulation (0.1 Hz) were measured.


RESULTS
Inhibition of plasma cholinesterase activity (by 93% and 89%, respectively) increased the onset time of suxamethonium from a median of 40 s (range, 20-45 s) to 131 s (range, 114-166 s; P = 0.009) and of mivacurium from a median of 52 s (range, 40-59 s) to 105 s (range, 90-125 s; P = 0.009). Inhibition of degradation decreased the effective dose of suxamethonium that resulted in 70% depression of the initial twitch height from 900 microg/kg (range, 400-1,000 microg/kg) to 150 microg/kg (range, 135-150 microg/kg) and of mivacurium from 100 microg/kg (range, 80-150 microg/kg) to 35 microg/kg (range, 20-50 microg/kg).


CONCLUSIONS
Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. Therefore, pharmacokinetics influence the onset time of submaximal neuromuscular block. These results imply that to obtain an ultrashort onset time, muscle relaxants should be developed that not only have a low affinity for the receptor but also rapidly disappear from plasma.
Beaufort
T M
TM
Research Group for Experimental Anesthesiology and Clinical Pharmacology, University of Groningen, The Netherlands. a.m.beaufort@anest.azg.nl
Nigrovic
V
V
Proost
J H
JH
Houwertjes
M C
MC
Wierda
J M
JM
D000818:Animals; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D002802:Cholinesterases / Q000097:blood; D007546:Isoquinolines / Q000378:metabolism* / Q000494:pharmacology; D008297:Male; D000077590:Mivacurium; D009467:Neuromuscular Depolarizing Agents / Q000378:metabolism*; D009469:Neuromuscular Junction / Q000187:drug effects*; D003473:Neuromuscular Nondepolarizing Agents / Q000378:metabolism*; D013390:Succinylcholine / Q000378:metabolism* / Q000494:pharmacology; D013552:Swine; D013770:Tetraisopropylpyrophosphamide / Q000494:pharmacology*
D002800:Cholinesterase Inhibitors; D007546:Isoquinolines; D009467:Neuromuscular Depolarizing Agents; D003473:Neuromuscular Nondepolarizing Agents; D013770:Tetraisopropylpyrophosphamide; D000077590:Mivacurium; D002802:Cholinesterases; D013390:Succinylcholine